ArticleCureus2026
Prognostic Role of Mid-Regional Proadrenomedullin in Patients Undergoing Emergency Laparotomy: An Exploratory Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveOur primary objective was to determine the ability of mid-regional proadrenomedullin (MR-proADM) levels to predict outcomes, i.e., mortality and clinical cure within 30 days in post-laparotomy patients. The secondary objective was to correlate MR-proADM with other markers of sepsis, such as procalcitonin (PCT) and lactate, and to determine the ability of MR-proADM levels to predict the presence or absence of sepsis on preoperative days 3, 5, and 7 in post-laparotomy patients. Methods: This was a single-center prospective pilot observational study. Patients ≥18 years of age who underwent emergency laparotomy (EL) under general anesthesia at a tertiary care hospital between January 2022 and July 2023 were enrolled. MR-proADM, lactate, PCT, and sequential organ failure assessment (SOFA) scores were measured pre-operatively and on days 3, 5, and 7. Detection of sepsis, clinical cure, and 30-day all-cause mortality were ascertained.
resultsMR-proADM demonstrated statistically significant correlation with PCT (p<0.001) at all time points, the SOFA score at preoperative, day 5, and day 7, and lactate on day 7 (p<0.001). MR-proADM levels were higher on days 5 and 7 in patients who failed to achieve clinical cure (p=0.0003 and 0.0004, respectively). At all time points, the discriminatory ability of MR proADM to distinguish sepsis from non-sepsis was good. A comparison of MR-proADM levels in patients with 30-day all-cause mortality was performed. The non-survivors had significantly elevated MR-proADM levels at all time points.
conclusionsMR-proADM is a valuable biomarker that correlates strongly with lactate, PCT, and the SOFA score and can help detect sepsis. Persistently higher values were associated with absence of clinical cure and 30-day all-cause mortality in patients undergoing EL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.